Clinical evaluation of immunotherapy: Are there differences between papillary and flat in situ bladder cancer?

Cancer Surveys

Volumn 31, Issue , 1998, Pages 99-108

  Lamm, Donald L ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; MITOMYCIN C; THIOTEPA;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CELLULAR IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 0031835497     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Abrams PH, Choa RG, Gaches CG, Ashken MH and Green NA (1981) A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. British Journal of Urology 53 585-587
2. Akaza H, Isaka S, Koiso K et al (1987) Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemotherapy and Pharmacology 20 (Supplement) 91-94
3. Asahi T, Matsumura Y, Tanahashi T et al (1980) The effects of intravesical instillation of thiotepa on the recurrence rate of bladder tumors. Acta Medica Okayama 34 43-45
4. Bast RC Jr, Zbar B, Borsos T et al (1974) BCG and cancer, 1. New England Journal of Medicine 290 1413-1415
5. Bohle A, Nowc Ch, Ulmer AJ et al (1990) Detection of urinary TNF, IL1, and IL2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2 175-181
6. Bohle A, Thanhauser A, Ulmer AJ et al (1993) Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. Journal of Urology 150 1032-1034
7. Bostwick D (1992) Natural history of early bladder cancer. Journal of Cellular Biochemistry 161 (Supplement) 31
8. Brosman SA (1982) Experience with bacillus Calmette-Guérin in patients with superficial bladder cancer. Journal of Urology 128 27-30
9. Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED and Lloyd-Davies RW (1976) Single dose intravesical thiotepa as an adjuvant to cyclodiathermy in the treatment of transitional cell bladder carcinoma. British Journal of Urology 48 55-57
10. Byar D and Blackard C (1977) Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 10 556-558
11. Herr HW, Pinsky CM, Whitmore WF, Sogani PG, Oettgen HF and Melamed MR (.1985) Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors. Urology 25 119-121
12. Herr HW, Pinsky CM, Whitmore WF, Sogani PG, Oettgen HF and Melamed MR (1986) Longterm effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. Journal of Urology 135 265-268
13. Hirao Y, Okajima E, Ozono S et al (1992) A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT. Cancer Chemotherapy and Pharmacology 30 (Supplement) S26-S30
14. 1 bladder carcinoma: a prospective cohort study. Journal of Urology 157 800-804
15. Huland H, Otto U, Drose M and Kloppel G (1984) Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression, and survival. Journal of Urology 132 27-29
16. Kim HH and Lee C (1989) Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. Journal of Urology 141 1337-1340
17. Koontz WW Jr, Prout GR Jr, Smith W, Frable WJ and Minnis JE (1981) The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. Journal of Urology 125 307-309
18. Krege S, Giani G, Meyer R et al (1996) A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin versus transurethral resection plus bacillus Calmette-Guérin. Journal of Urology 156 962-966
19. Kurth KH, Debruyne FJM, Senge T et al (1985) Adjuvant chemotherapy of superficial transitional cell carcinoma: an EORTC randomized trial comparing doxorubicin hydrochloride, ethoglucid and TUR alone, In: Schroeder FH and Richards B (eds). Part B: Superficial Bladder Tumors (EORTC Genitourinary Group Monograph 2, part B), pp 135-142, Alan R Liss, New York
20. Lamm DL (1985) Bacillus Calmette-Guérin immunotherapy for bladder cancer. Journal of Urology 134 40-42
21. Lamm DL (1992a) Carcinoma in situ. Urologic Clinics of North America 19 499-508
22. Lamm DL (1992b) Long-term results of intravesical therapy for superficial bladder cancer. Urologic Clinics of North America 19 573-580
23. Lamm DL (1995) BCG immunotherapy for carcinoma in situ of the bladder. Oncology 9 947-956
24. Lamm DL, Reichert FD, Harris SC and Lucio RM (1982a) Immunotherapy of murine transitional cell carcinoma. Journal of Urology 128 1104-1108
25. Lamm DL, Thor DE, Stogdill VD and Radwin HM (1982b) Bladder cancer immunotherapy. Journal of Urology 128 931-935
26. Lamm DL, Sarosdy MF, Grossman HB et al (1990) Maintenance vs. nonmaintenance BCG immunotherapy of superficial bladder cancer: a Southwest Oncology Group study. Journal of Urology 143 [Abstract 610, p 341]
27. Lamm DL, Blumenstein BA and Crawford ED (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. New England Journal of Medicine 325 1205-1209
28. Lamm DL, Blumenstein BA and Crawford ED (1995a) Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomyein C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder: a Southwest Oncology Group study. Urologic Oncology 1 119-126
29. Lamm DL, Riggs DR, Trayneus CL, and Naeyo ON (1995b) Failure of current intravesical cell carcinomas of the bladder. Journal of Urology 53 1444-1450
30. Lamm DL and Torti F (1996) Bladder cancer. Ca - A Cancer Journal for Clinicians 46 103-112
31. Lamm DL, Blumenstein B, Sarosdy MF, Grossman B and Crawford ED (1997) Significant longterm patient benefit with BCG maintenance therapy: a Southwest Oncology Group study. Journal of Urology 157 [Abstract 831, p 213]
32. Malmstrom Lundholm C, Norlen JB and Ekman P et al (1996) A randomized prospective study comparing long-term intravesical instillations of mitomyein C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Journal of Urology 156 372-376
33. Medical Research Council (1985) The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. British Journal of Urology 57 680-683
34. Melekos M D (1993) Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule. Oncology 50 450-455
35. Melekos MD, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G and Dauaher H (1993) Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. Journal of Urology 149 744-746
36. Netto NR and Lemos GC ( 1983) A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. Journal of Urology 129 33-34
37. Nüjima T, Akaza H, Koiso K and the Japanese Urologic Cancer Research Group for Adriamycin (1983) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemotherapy 2 (Supplement) 579-583
38. Nocks BN, Nieh PT and Prout GR Jr (1979) A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thiotepa. Journal of Urology 122 27-29
39. O'Donnell MA, Xiaohong C and DeWolf WC (1996) Maturation of the cytokine immune response to bacillus Calmette-Guérin (BCG) in the bladder: implications for treatment schedules. Journal of Urology 155 568A
40. 1 papillary carcinoma of the bladder. Journal of Urology 149 749-752
41. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D and Garbeglio A (1991) A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? Journal of Urology 146 32-35
42. 1 bladder cancer. Journal of Urology 155 492A [Abstract 727, p 492]
43. Prescott S, James K, Hargreave TB et al (1989) Immunopathological effects of intravesical BCG therapy. In: Debruyne FMJ, Denis L and van der Meijden ADPM (eds). BCG in Superficial Bladder Cancer (EORTC Genitourinary Group Monograph 6), pp 93-105, Alan R Liss, New York
44. Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR and Friedell GH for the National Bladder Cancer Collaborative Group (1983) Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. Journal of Urology 130 677-680
45. Ratliff TL (1994) Mechanism of action of intravesical BCG for superficial bladder cancer, In: Pagano F and Bassi P (eds). BCG Immunotherapy In Bladder Cancer, pp 25-31, Cooperative Libraria Editrice Universita di Padova, Padova
46. Ratliff TL and Catalona WJ (1989) Depressed proliferative responses in patients treated with 12 weeks of intravesical BGG. Journal of Urology 141 [Abstract 244, p 230]
47. Rawls WH, Lamm DL, Lowe BA et al (1990) Fatal sepsis following intravesical bacillus Calmette-Guérin administration for bladder cancer. Journal of Urology 144 1328-1330
48. Reichert DF and Lamm DL (1984) Long term protection in bladder cancer following intralesional immunotherapy. Journal of Urology 132 570-573
49. Rubben H, Lutzeyer W, Fischer N et al (1988) Natural history and treatment of low and high risk superficial bladder tumors. Journal of Urology 139 283-285
50. Schulman CC, Robinson M, Denis L et al (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, VM-26 and TUR alone. European Urology 8 207-210
51. Tolley DA, Hargreave TB, Smith PH et al (1988) Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer. British Medical Journal 296 1759-1763
52. 1, bladder tumours. British Journal of Urology 68 380-384
53. Walkes MC, Master JRW, Parris CN et al (1986) Intravesical chemotherapy: in vitro studies on the relationship between close arid toxicity. Virology Research 14 137-139
54. Zincke H, Utz DC, Taylor WF, Myers RP and Leary FJ (1983) Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. Journal of Urology 129 505-508